Prolonged Clinical Follow-up of OPTIMA-5

Arm 1 and 2 inclusion and exclusion criteria Inclusion Criteria: 1. Age 18-75 years, weight ≥45 kg; 2. Diagnosed as STEMI (meeting the following two criteria simultaneously): i. Ischemic chest pain lasts ≥30 minutes; ii. Electrocardiogram indicates that ST-segment elevation ≥2 mm in 2 or more contiguous precordial leads or ≥1 mm in 2 or more peripheral leads; 3. Time from onset of persistent chest pain to randomization \<12 hours; 4. Primary PCI expected to be performed within 120 minutes. Exclusion Criteria: 1. Cardiogenic shock; 2. Active bleeding or at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 1 month); 3. Ischemic stroke or TIA in the past 6 months; 4. History of hemorrhagic stroke; 5. Platelet count \<100×109/L or hemoglobin \<100 g/L; 6. Known intracranial aneurysm; 7. Severe trauma, surgery or head injury within 1 month; 8. Suspected aortic dissection or infective endocarditis; 9. Recent puncture with difficult hemostasis by compression (eg, visceral biopsy, compartment puncture); 10. Currently taking anticoagulants; 11. Poorly controlled hypertension ( ≥180/110 mmHg); 12. Hepatic or renal impairment (glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, or γ -glutamyl transferase \>2.5 times upper limit of normal value; creatinine \>1.5 times upper limit of normal value); 13. Known allergy to r-SAK; 14. Pregnancy, lactation, or planning for pregnancy; 15. History of myocardial infarction or CABG; 16. Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset; 17. Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators. Arm 3 inclusion and exclusion criteria Inclusion criteria 1. Age ≥18, ≤75 years old, weight ≥45kg, gender is not limited； 2. Taking maintenance dose of aspirin and ticagrelor for more than 3 days, or taking loading dose of aspirin (300mg) and ticagrelor (180mg); 3. Inpatients with suspected coronary atherosclerotic heart disease scheduled for coronary angiography or interventional therapy. Exclusion criteria 1. Patients who had received r-SAK thrombolytic therapy before; 2. Previous diagnosis of Staphylococcus aureus infection; 3. Patients who were participating in other clinical trials; 4. Other patients considered unsuitable for inclusion by the investigators.